What You Should Know:
Culmination Bio, a data and technology company combining clinical and biospecimen data, announced a partnership with BillionToOne, Inc., a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all.Culmination Bio and BillionToOne are working together to leverage their respective strengths in order to facilitate the development and validation of robust and impactful oncology
Read More
Precision Medicine Oncology | Molecular Profiling | News, Analysis, Insights
C2i Genomics & AstraZeneca Partner to Advance Cancer Therapy
What You Should Know:
- C2i Genomics, a cancer intelligence company, today announced a strategic collaboration with AstraZeneca, a global life sciences and pharmaceutical leader.
- The two companies have collaborated to evaluate the potential of whole-genome minimal residual disease (MRD) testing across solid cancers.
- Expanding on a completion of AstraZeneca’s accelerator BeyondBio SCALE program for start-ups and successful technology validation, C2i Genomics and AstraZeneca
Read More
OncoHost Raises $35M for AI-Powered Precision Oncology Platform
What You Should Know:
- OncoHost, an AI-powered precision oncology platform, today announced a $35M Series C funding round led by ALIVE Israel HealthTech VC, as well as other prominent investors. Additional investors included leading Israeli financial firm Leumi Partners, Israel’s largest pension fund Menora Mivtachim, OurCrowd and other existing investors.
- The funding will go towards expanding OncoHost’s ongoing multicenter PROPHETIC trial as well as support its upcoming
Read More
Mayo Clinic Partners with VUNO to Develop AI-Driven Precision Oncology Solutions
What You Should Know:
- Mayo Clinic has signed a research agreement with VUNO, a global medical artificial intelligence (AI) company to develop advanced AI-driven precision oncology solutions to deliver precision oncology care.
- Through this research agreement, VUNO will establish a collaboration with Mayo Clinic to develop innovative AI and machine learning solutions for more precise diagnosis, prognosis and treatment stratification in cancer.
- This collaborative agreement combines
Read More
Syapse, Pfizer Extends Collaboration to Generate Real-World Evidence in Breast Cancer
What You Should Know:
- Syapse, a real-world evidence company that informs cancer care, announced that it will extend its collaboration with Pfizer to generate real-world evidence in breast cancer.
- This is the third phase of the collaboration, which was first announced in 2019 and renewed in 2021.
Generate Real-World Evidence in Breast Cancer
As part of the next phase of the collaboration, Syapse will provide insights and services to Pfizer, using the Syapse Learning Health Network
Read More
Notable Labs Launches by Acquiring Rights to Volasertib – Will Use Data, AI to Fast-Track Cancer Treatment
What You Should Know:
- Coming out of stealth, Notable Labs, a pioneer and developer of predictive precision medicines, is acquiring worldwide development and commercial rights to volasertib, a PLK-1 inhibitor in acute myeloid leukemia (AML) from Oncoheroes.
- Notable will leverage its high-fidelity Predictive Precision Medicines Platform to identify and select volasertib-responsive patients prior to their treatment and fast-track volasertib’s clinical development
Read More
Cedars-Sinai Cancer Launches ‘Molecular Twin’ Initiative for Precision Cancer Treatment
What You Should Know:
- Cedars-Sinai Cancer and Tempus, a provider of artificial intelligence and precision medicine, are harnessing the power of big data and AI to design personalized cancer treatment options by creating virtual replicas of patients' DNA, RNA, protein and other information to help identify the most effective approach to each individual's disease.
- By creating these "molecular twins," scientists can genetically classify cancer genes and proteins of particular tumors
Read More
Foundation Medicine Integrates with Epic EMR for Genomic Insights for Precision Cancer Care
What You Should Know:
- Foundation Medicine (FMI) announced today a partnership to integrate its comprehensive genomic testing services into Epic’s electronic medical record (EMR) platform, making it easier for oncologists to order comprehensive genomic tests (CGP), review results, continually access clinical and genomic information and share among their care teams in order to develop personalized treatment plans quickly and efficiently for their patients. See the full release
Read More
AWS, PHDA Collaborate to Develop Breast Cancer Screening and Depression Machine Learning Models
What You Should Know:
- Amazon Web Services (AWS) and the Pittsburgh Health Data Alliance (PHDA) announce a collaboration to produce more accurate machine learning models for breast cancer screening and depression.
- In work funded through the PHDA-AWS collaboration, a research team led by Shandong Wu, an associate professor at the University of Pittsburgh Department of Radiology, is using deep-learning systems to analyze mammograms in order to predict the short‐term risk of developing
Read More
CancerIQ Raises $5M to Expand Genetic Cancer Risk Assessment Platform
What You Should Know:
- CancerIQ raises $5M in Series A funding led by HealthXVentures to accelerate the growth of its genetic cancer risk assessment platform to identify and manage patients at high risk of cancer.
- CancerIQ’s technology enables hospitals to use genomics
to personalize the prevention and early detection of cancer.
- Two new hires recently joined CancerIQ’s newly formed
Integrated Products team from Epic, with the goal of advancing CancerIQ’s
integration with leading
Read More
